SCHEMBL684026

SCHEMBL684026

Cc1cccc(N2CCN(Cn3c(=O)c4c(ncn4C)n(C)c3=O)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.49
HTR2A P28223 1/20 0.48
ADORA2B P29275 5/20 0.46
KCNH2 Q12809 2/20 0.46
GLA P06280 1/20 0.46
BLM P54132 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 1/20 0.46
HTR7 P34969 1/20 0.46
HTR6 P50406 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683652 0.90 MAPK1 (0.55) MAPK1HTR2AGLAKDM4EUSP2
SCHEMBL684023 0.88 HTR2A (0.58) MAPK1HTR2AADORA2BGLABLM
SCHEMBL684068 0.88 ADORA2B (0.50) MAPK1HTR2AADORA2BKCNH2HTR7
SCHEMBL682830 0.87 ADORA2B (0.50) HTR2AADORA2BGLABLMUSP2
SCHEMBL684377 0.87 MAPK1 (0.47) MAPK1HTR2AADORA2BGLABLM
SCHEMBL683665 0.87 ADORA2B (0.47) MAPK1HTR2AADORA2BGLABLM
SCHEMBL683657 0.86 DRD2 (0.51) MAPK1HTR2AKCNH2ALDH1A1TSHR
SCHEMBL683667 0.86 ADORA2B (0.46) MAPK1HTR2AADORA2BGLABLM
SCHEMBL682832 0.85 MAPT (0.49) MAPK1HTR2AADORA2BGLABLM
SCHEMBL683640 0.84 HTR2A (0.51) MAPK1HTR2AADORA2BGLABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF MAPK1 470/4885HTR2A 1201/4885ADORA2B 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.